Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech, ImmunoGen in second antibody deal

The five-year deal allows DNA to use IMGN's maytansinoid Tumor-

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE